- Home
- CNS vs ZLAB Comparison
CNS vs ZLAB Comparison
Compare CNS & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNS
- ZLAB
- Stock Information
- Founded
- CNS 1986
- ZLAB 2013
- Country
- CNS United States
- ZLAB China
- Employees
- CNS N/A
- ZLAB N/A
- Industry
- CNS Investment Managers
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- CNS Finance
- ZLAB Health Care
- Exchange
- CNS Nasdaq
- ZLAB Nasdaq
- Market Cap
- CNS 4.2B
- ZLAB 3.6B
- IPO Year
- CNS 2004
- ZLAB 2017
- Fundamental
- Price
- CNS $74.87
- ZLAB $34.55
- Analyst Decision
- CNS Hold
- ZLAB Buy
- Analyst Count
- CNS 3
- ZLAB 4
- Target Price
- CNS $81.00
- ZLAB $47.37
- AVG Volume (30 Days)
- CNS 175.7K
- ZLAB 1.0M
- Earning Date
- CNS 07-16-2025
- ZLAB 08-05-2025
- Dividend Yield
- CNS 3.34%
- ZLAB N/A
- EPS Growth
- CNS 18.98
- ZLAB N/A
- EPS
- CNS 3.06
- ZLAB N/A
- Revenue
- CNS $529,174,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- CNS $5.81
- ZLAB $44.07
- Revenue Next Year
- CNS $12.38
- ZLAB $49.13
- P/E Ratio
- CNS $24.36
- ZLAB N/A
- Revenue Growth
- CNS 8.82
- ZLAB 43.72
- 52 Week Low
- CNS $68.99
- ZLAB $16.01
- 52 Week High
- CNS $110.67
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- CNS 42.77
- ZLAB 49.05
- Support Level
- CNS $73.47
- ZLAB $36.36
- Resistance Level
- CNS $77.18
- ZLAB $44.34
- Average True Range (ATR)
- CNS 1.48
- ZLAB 1.45
- MACD
- CNS -0.20
- ZLAB -0.16
- Stochastic Oscillator
- CNS 28.81
- ZLAB 39.20
About CNS Cohen & Steers Inc
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.